TCL Archive “Miracle-Gro for Cancer?” ODAC Members Vent At Amgen And J&J Over Claims, Advertising. By Cancer History Project May 18, 2007
TCL Archive FDA Should Delay Provenge Decision Pending Definitive Trial Results, ODAC Chairman Writes. By Cancer History Project April 27, 2007
TCL Archive If You Were On ODAC: Experts Suggest Questions For May 10 Advisory Meeting. By Cancer History Project March 16, 2007
TCL Archive EPO Controversy: ODAC To Review EPO Agents in May; SEC Probes Amgen’s Delay in Study Disclosure. By Cancer History Project March 2, 2007
TCL Archive ODAC Nixes Abraxane for Adjuvant Breast Cancer, While Genasense Falls Victim to Its Randomized Trial. By Cancer History Project September 8, 2006
TCL Archive FDA Approves Gemzar For Ovarian Cancer, Contradicting ODAC Recommendation; Continues Agency Trend to Recognize Progression-Free Survival As An Endpoint. By Cancer History Project July 21, 2006
TCL Archive ODAC Meets at ASCO, Recommends Approval Of Dasatinib For CML. By Cancer History Project June 9, 2006
TCL Archive ODAC Finds Increase In Progression-Free Survival Unconvincing To Approve sNDA For Gemzar In Advanced Ovarian Cancer. By Cancer History Project March 24, 2006
ArticleSpotlight Article A Vote for Cancer: Tobacco Advertising and Presidential Elections By The Center for the Study of Tobacco and Society